Biosimulation Market worth 2,107.99 M USD by 2020

Monday 24 August 2015, Amsterdam

The report, now available on ASDReports, “Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by Application (Drug Discovery & Development, Preclinical, Clinical Trial), by End Users - Global Forecast to 2020”, The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020.

The report provides a detailed overview of the major drivers, restraints, and opportunities impacting the global biosimulation market along with the estimates and forecasts of the revenue and market share analysis.

The global biosimulation market is poised to witness rapid growth between 2015 and 2020. A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the biosimulation market. Other growth drivers include the need to curtail costs, growth in the biologics and biosimilars markets, increased use of personalized medicine, technological advancements, and periodic product upgradation.

The market is segmented on the basis of product, application, and end user. By product, the market includes software and services. The software segment is further classified into molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trail design software, toxicity prediction software, and other software (QSP, visualizing and analytical software). The services segment includes in-house and external/contract services. Software will hold the largest share of the biosimulation market in 2015, while services will grow at the highest CAGR.

The applications included in this report are drug discovery, drug development, and others. The drug development segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment (defense, industrial bioprocessing, nutraceuticals, and agri-food production) is expected to be the fastest growing.

End users included in this report are academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities and other end users (defense, nutraceuticals companies, and food and agricultural companies). Of these, the pharmaceutical and biotechnology companies will hold the largest share of the biosimulation market in 2015. Pharmaceutical and biotechnology companies are expected to form the fastest-growing end-user segment.

The geographic segments included in this report are the North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to hold the largest share of this market in 2015, while Europe is expected to grow at the fastest rate. Growth in the European biosimulation market will primarily be driven by increased government funding and the large number of pharmaceuticals and biotechnology companies in this region.

Major players in the global biosimulation market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systèmes SA (France), Schrödinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).
Biosimulation Market - Global Forecast to 2020

Biosimulation Market - Global Forecast to 2020

Publish date : July 2015
Report code : ASDR-211571
Pages : 149

Biosimulation Market - Global Forecast to 2022

Biosimulation Market - Global Forecast to 2022

Publish date : January 2018
Report code : ASDR-436342
Pages : January 2018

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News